<DOC>
	<DOCNO>NCT02517736</DOCNO>
	<brief_summary>The objective study determine efficacy toxicity sorafenib metastatic uveal melanoma . The main objective determine non-tumor progression rate 24 week initiation treatment sorafenib dose 800 mg / day</brief_summary>
	<brief_title>Study Multicentre Evaluating Effectiveness Toxicity Sorafenib ( Nexavar® ) Adult Patients With Uveal Melanoma Metastatic Dissemination</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Male female 18 year old suffering uveal melanoma metastasis At least one measurable metastases 10 mm acoording Response Evaluation Criteria Solid Tumors ( RECIST ) At least 28 day previous treatment ( systemic major surgery ) Performance Index ( WHO ≤ 2 ≥ 70 % Karnofsky ) Weight loss compare pre morbid weight &lt; 20 % last 12 month White blood cell least 3000 / mm 3 , polynuclear neutrophils less 1500 / mm3 , platelet least 100,000 / mm3 , hemoglobin least 9.0 g / dl Total Bilirubin ≤1.5 x upper limit normal ( ULN ) ( less equal 2.5 liver metastasis ) , ASAT ALAT ≤ 2.5 x ULN ( ≤ 5 liver metastasis ) Serum Creatinine ( calculate use cockcroftGault method ) ≤ 1.5 x ULN , Amylase lipase &lt; 1.5 x ULN prothrombin rate international normalize ratio ( INR ) activate partial thromboplastin time ( aPTT ) ≤ 1.5 x ULN . Possibility use low molecular weight heparin place anti vitamin K treatment high life expectancy equal 3 month Negative pregnancy test woman childbearing age use method contraception treatment No one benefit Social Security scheme Informed consent sign patient legal representative • Patient receive 2 line treatment ( chemotherapy immunotherapy ) , whatever indication Major surgery ( exclude possible diagnostic biopsy ) radiation therapy 4 week precede inclusion single liver metastasis treatable surgery active peptic ulcer , uncontrolled Other progressive malignancy treatment ( except basal cell carcinoma ) Cardiac arrhythmia require antiarrhythmic ( exclude betablockers digoxin chronic atrial fibrillation ) , active ischemic coronary disease ( myocardial infarction within last 6 month ) , heart failure &gt; New York Heart Association ( NYHA ) class II Bacterial fungal infection active ( grade &gt; 2 Common Toxicity Criteria Adverse Effects ( CTCAE ) v4.03 ) know HIV infection chronic hepatitis B C cerebral meningeal tumor metastasis ( symptomatic asymptomatic ) epileptic disease require antiepileptic take Previous history organ transplantation peripheral stem cell Patient kidney dialysis Concomitant treatment cytochrome P450 3A4 ( CYP3A4 ) inducer rifampin , St. John 's wort , phenytoin , carbamazepine , phenobarbital dexamethasone Prior therapy bevacizumab target therapy Known suspect allergy sorafenib Any unstable chronic illness jeopardize patient safety compliance Women pregnant lactate coagulopathy Uncontrolled hypertension Inability swallow Failure submit medical monitoring trial due geographical , social psychic Persons deprive liberty supervision Patient refuse ambulatory care Patient simultaneously participate another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>